Stockscreener 앱 받기
7.45
1.84%
-0.14
시간 외 거래:
7.59
0.14
+1.88%
전일 마감가:
$7.59
열려 있는:
$7.63
하루 거래량:
253.26K
Relative Volume:
0.70
시가총액:
$175.75M
수익:
-
순이익/손실:
$-52.07M
주가수익비율:
-35.87
EPS:
-0.2077
순현금흐름:
$-44.93M
1주 성능:
-1.46%
1개월 성능:
-2.36%
6개월 성능:
-17.22%
1년 성능:
-27.66%
1일 변동 폭
$7.40
$7.65
1주일 범위
$7.37
$7.80
52주 변동 폭
$4.81
$13.88
Cybin Inc Stock (CYBN) Company Profile
명칭
Cybin Inc
전화
908 764 8385
주소
100 King Street West, Suite 5600, Toronto
CYBN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CYBN
Cybin Inc
|
7.45 | 175.98M | 0 | -52.07M | -44.93M | -0.2077 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Cybin Inc Stock (CYBN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-13 | 개시 | Guggenheim | Buy |
| 2021-11-19 | 다운그레이드 | Maxim Group | Buy → Hold |
Cybin Inc 주식(CYBN)의 최신 뉴스
Cybin gains Irish Medicines Board approval for major depressive disorder trial - Yahoo Finance
Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder - BioSpace
Cybin Inc. shares rise 1.13% intraday after receiving approval to initiate EMBRACE trial in Europe. - AInvest
Psychedelic: Cybin receives European approval for EMBRACE study - TipRanks
Cybin receives European approval for EMBRACE trial - TipRanks
Cybin Gets European Approval For EMBRACE Study Of CYB003 For Major Depressive Disorder - Nasdaq
Cybin Secures European Approval for EMBRACE Study in Major Depressive Disorder - TipRanks
Cybin receives European approval for phase 3 depression drug trial By Investing.com - Investing.com Nigeria
Cybin receives European approval for phase 3 depression drug trial - Investing.com
Breakthrough Depression Drug Shows 71% Remission Rate as Phase 3 Trial Expands to Europe - Stock Titan
Cybin CEO to Speak at Canaccord Genuity Growth Conference - TipRanks
Cybin to Participate in the Canaccord Genuity 45th Annual Growth Conference - Business Wire
What are the latest earnings results for Cybin Inc.Achieve rapid wealth accumulation through smart investing - Jammu Links News
Cybin Inc. Stock Analysis and ForecastFree Market Dynamics Reports - Jammu Links News
How volatile is Cybin Inc. stock compared to the marketCapitalize on emerging investment opportunities - Jammu Links News
What institutional investors are buying Cybin Inc. stockCapitalize on market trends before they peak - Jammu Links News
What are analysts’ price targets for Cybin Inc. in the next 12 monthsUnlock powerful market analysis and alerts - Jammu Links News
Is Cybin Inc. stock overvalued or undervaluedUnstoppable trading performance - Jammu Links News
How many analysts rate Cybin Inc. as a “Buy”Achieve consistent profits with proven methods - Jammu Links News
Is Cybin Inc. a good long term investmentSuperior profit margins - Jammu Links News
When is Cybin Inc. stock expected to show significant growthAchieve breakthrough financial results - Jammu Links News
Why is Cybin Inc. stock attracting strong analyst attentionInvest smarter with data-backed trading alerts - Jammu Links News
What are Cybin Inc. company’s key revenue driversGet expert insights on market-moving stocks - Jammu Links News
Cybin Announces $1 Billion Mixed Securities Shelf Filing to Enhance Financial Flexibility - AInvest
Cybin Inc. Schedules Virtual Annual General Meeting for August 2025 - MSN
Cybin Inc. May Be Forming Higher Low — Chartwatchers AlertFundamental + Technical Hybrid Stock Tips Shared - beatles.ru
Should I hold or sell Cybin Inc. stock in 2025Real Time Insights For 2025 - jammulinksnews.com
What is the dividend policy of Cybin Inc. stockFree Risk Assessment Services - Jammu Links News
What are the technical indicators suggesting about Cybin Inc.Access high-yield investment alerts now - Jammu Links News
How Cybin Inc. stock performs during market volatilitySolid Return Trade Selections - metal.it
What analysts say about Cybin Inc. stockSuperior portfolio returns - PrintWeekIndia
Cybin, Inc: CYB003 Vs. GH001Duration, Durability and Protocol Execution - Smartkarma
What drives Cybin Inc. stock pricePowerful market insights - PrintWeekIndia
Will Cybin Inc. stock benefit from AI tech trendsFree Predictions - Jammu Links News
Cybin Inc (CYBN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):